CO6460726A2 - Derivado de 5-hidroxi-pirimidin-4-carboxamida - Google Patents
Derivado de 5-hidroxi-pirimidin-4-carboxamidaInfo
- Publication number
- CO6460726A2 CO6460726A2 CO12082335A CO12082335A CO6460726A2 CO 6460726 A2 CO6460726 A2 CO 6460726A2 CO 12082335 A CO12082335 A CO 12082335A CO 12082335 A CO12082335 A CO 12082335A CO 6460726 A2 CO6460726 A2 CO 6460726A2
- Authority
- CO
- Colombia
- Prior art keywords
- group
- ring
- alkyl group
- optionally substituted
- heterocyclic ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Abstract
La presente invención proporciona un compuesto que potencia la producción de eritropoietina. Específicamente, se da a conocer un compuesto representado por fórmula (1):en donde: R1 representa un grupo representado por la fórmula (1A):en donde R4 y R5 representan independientemente H, un átomo de halógeno, o un grupo alquilo; R6 representa H, un átomo de halógeno, un grupo alquilo, o similares; R7 representa un grupo hidroxi-alquilo opcionalmente sustituido, un grupo hidroxi-halo alquilo opcionalmente sustituido, un grupo alcoxi-alquilo opcionalmente sustituido, o similares; el grupo de sustituyentes a incluye un grupo oxo, un grupo hidroxilo, un grupo amino, y similares; el anillo Q1 representa un grupo de anillo heterocíclico monocíclico; el anillo Q2 representa un grupo de anillo de hidrocarburo monocíclico, o un grupo de anillo heterocíclico monocíclico; el anillo Q3 representa un grupo de anillo de hidrocarburo monocíclico, o un grupo de anillo heterocíclico monocíclico; y X representa un enlace individual, un grupo metileno, un grupo etileno, o similares; R2 representa un grupo alquilo, o un grupo metil-sulfanilo; y R3 representa H, o un grupo metilo, o similares.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009242884 | 2009-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6460726A2 true CO6460726A2 (es) | 2012-06-15 |
Family
ID=43900350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO12082335A CO6460726A2 (es) | 2009-10-21 | 2012-05-18 | Derivado de 5-hidroxi-pirimidin-4-carboxamida |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8785462B2 (es) |
| EP (1) | EP2492266B1 (es) |
| JP (1) | JP5718236B2 (es) |
| KR (1) | KR101665749B1 (es) |
| CN (1) | CN102712619B (es) |
| AU (1) | AU2010308942C1 (es) |
| BR (1) | BR112012009452A2 (es) |
| CA (1) | CA2780533C (es) |
| CO (1) | CO6460726A2 (es) |
| CY (1) | CY1116974T1 (es) |
| DK (1) | DK2492266T3 (es) |
| ES (1) | ES2549503T3 (es) |
| HK (1) | HK1174621A1 (es) |
| HR (1) | HRP20151110T1 (es) |
| HU (1) | HUE026128T2 (es) |
| IL (1) | IL219243A (es) |
| MX (1) | MX2012004714A (es) |
| MY (1) | MY163022A (es) |
| NZ (1) | NZ600017A (es) |
| PL (1) | PL2492266T3 (es) |
| PT (1) | PT2492266E (es) |
| RS (1) | RS54323B1 (es) |
| RU (1) | RU2550693C2 (es) |
| SI (1) | SI2492266T1 (es) |
| SM (1) | SMT201500268B (es) |
| TW (2) | TW201124397A (es) |
| WO (2) | WO2011049126A1 (es) |
| ZA (1) | ZA201202899B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5718236B2 (ja) | 2009-10-21 | 2015-05-13 | 第一三共株式会社 | ５−ヒドロキシピリミジン−４−カルボキサミド誘導体 |
| WO2013147214A1 (ja) * | 2012-03-30 | 2013-10-03 | 第一三共株式会社 | ５－ヒドロキシピリミジン－４－カルボキサミド誘導体 |
| CN104334528A (zh) * | 2012-03-30 | 2015-02-04 | 第一三共株式会社 | (2-杂芳基氨基)琥珀酸衍生物 |
| IN2015DN02814A (es) * | 2012-10-26 | 2015-09-11 | Asahi Glass Co Ltd | |
| WO2016054804A1 (en) * | 2014-10-10 | 2016-04-14 | Merck Sharp & Dohme Corp. | Substituted pyrimidines as inhibitors of hif prolyl hydroxylase |
| CN108367007A (zh) * | 2015-12-16 | 2018-08-03 | 第三共株式会社 | 用于伤口的治疗剂 |
| JPWO2017175859A1 (ja) * | 2016-04-08 | 2019-06-06 | 学校法人慶應義塾 | 乳酸アシドーシスの予防又は治療のための医薬 |
| WO2019099294A1 (en) * | 2017-11-14 | 2019-05-23 | Merck Sharp & Dohme Corp. | Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| TW201936598A (zh) | 2018-02-19 | 2019-09-16 | 日商第一三共股份有限公司 | 炎症性腸病治療劑 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003049686A2 (en) | 2001-12-06 | 2003-06-19 | Fibrogen, Inc. | Stabilization of hypoxia inducible factor (hif) alpha |
| KR100932169B1 (ko) | 2003-06-06 | 2009-12-16 | 피브로겐, 인크. | 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용 |
| WO2005014534A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| CN101394843A (zh) * | 2005-06-06 | 2009-03-25 | 菲布罗根公司 | 使用HIFα稳定剂的改进的贫血治疗 |
| WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| JP2009537558A (ja) | 2006-05-16 | 2009-10-29 | スミスクライン・ビーチャム・コーポレイション | プロリルヒドロキシラーゼ阻害剤 |
| JO2934B1 (en) * | 2006-06-23 | 2015-09-15 | سميث كلاين بيتشام كوربوريشن | Prolyl hydroxylase inhibitors |
| ES2922078T3 (es) | 2006-06-26 | 2022-09-07 | Akebia Therapeutics Inc | Inhibidores de prolil hidroxilasa y métodos de uso |
| CL2008000066A1 (es) * | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
| TW200845994A (en) * | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: prolyl hydroxylase inhibitors |
| MX2010010209A (es) * | 2008-03-18 | 2010-10-05 | Merck Sharp & Dohme | 4-hidroxipirimidina-5-carboxamidas sustituidas. |
| US20110112103A1 (en) | 2008-04-22 | 2011-05-12 | Daiichi Sankyo Company, Limited | 5-hydroxypyrimidine-4-carboxamide compound |
| JP5718236B2 (ja) | 2009-10-21 | 2015-05-13 | 第一三共株式会社 | ５−ヒドロキシピリミジン−４−カルボキサミド誘導体 |
| JP2011105708A (ja) * | 2009-10-21 | 2011-06-02 | Daiichi Sankyo Co Ltd | ５−ヒドロキシピリミジン−４−カルボキサミド化合物を含有する医薬組成物 |
| WO2011132633A1 (ja) | 2010-04-19 | 2011-10-27 | 第一三共株式会社 | 置換５－ヒドロキシピリミジン－４－カルボキサミド化合物 |
-
2010
- 2010-10-20 JP JP2011537279A patent/JP5718236B2/ja active Active
- 2010-10-20 MX MX2012004714A patent/MX2012004714A/es active IP Right Grant
- 2010-10-20 TW TW099135716A patent/TW201124397A/zh unknown
- 2010-10-20 MY MYPI2012001770A patent/MY163022A/en unknown
- 2010-10-20 WO PCT/JP2010/068476 patent/WO2011049126A1/ja active Application Filing
- 2010-10-20 US US13/503,340 patent/US8785462B2/en active Active
- 2010-10-20 HU HUE10824975A patent/HUE026128T2/en unknown
- 2010-10-20 PT PT108249756T patent/PT2492266E/pt unknown
- 2010-10-20 CN CN201080058211.0A patent/CN102712619B/zh active Active
- 2010-10-20 WO PCT/JP2010/068477 patent/WO2011049127A1/ja active Application Filing
- 2010-10-20 RU RU2012120749/04A patent/RU2550693C2/ru active
- 2010-10-20 SI SI201031047T patent/SI2492266T1/sl unknown
- 2010-10-20 RS RS20150670A patent/RS54323B1/en unknown
- 2010-10-20 CA CA2780533A patent/CA2780533C/en active Active
- 2010-10-20 EP EP10824975.6A patent/EP2492266B1/en active Active
- 2010-10-20 DK DK10824975.6T patent/DK2492266T3/en active
- 2010-10-20 ES ES10824975.6T patent/ES2549503T3/es active Active
- 2010-10-20 AU AU2010308942A patent/AU2010308942C1/en active Active
- 2010-10-20 KR KR1020127010014A patent/KR101665749B1/ko active IP Right Grant
- 2010-10-20 TW TW99135723A patent/TWI469975B/zh active
- 2010-10-20 NZ NZ600017A patent/NZ600017A/en unknown
- 2010-10-20 BR BR112012009452A patent/BR112012009452A2/pt not_active Application Discontinuation
- 2010-10-20 PL PL10824975T patent/PL2492266T3/pl unknown
-
2012
- 2012-04-17 IL IL219243A patent/IL219243A/en active IP Right Grant
- 2012-04-19 ZA ZA2012/02899A patent/ZA201202899B/en unknown
- 2012-05-18 CO CO12082335A patent/CO6460726A2/es unknown
-
2013
- 2013-02-04 HK HK13101564.9A patent/HK1174621A1/xx unknown
-
2015
- 2015-10-21 HR HRP20151110TT patent/HRP20151110T1/hr unknown
- 2015-10-28 SM SM201500268T patent/SMT201500268B/it unknown
- 2015-11-24 CY CY20151101058T patent/CY1116974T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6460726A2 (es) | Derivado de 5-hidroxi-pirimidin-4-carboxamida | |
| CY1119220T1 (el) | Μονοκυκλικο παραγωγο πυριδινης | |
| PE20210549A1 (es) | Derivado de amino-metil piperidina como inhibidor de quinasa | |
| CY1120477T1 (el) | Ενεργοποιητης του υποδοχεα που ενεργοποιειται απο πολλαπλασιαστες των υπεροξεισωματων | |
| CR20110169A (es) | Compuestos de pirrol | |
| PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| ECSP12012212A (es) | Derivados de ariletinilo | |
| ES2653265T3 (es) | Morfinanos sustituidos y el uso de éstos | |
| BRPI1009637A2 (pt) | composto, composição e uso de um composto | |
| CR10250A (es) | Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g | |
| DOP2011000281A (es) | Derivados de benzofurano | |
| AR057891A1 (es) | Compuestos de oxazol y composicion farmaceutica | |
| AR093184A1 (es) | Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden | |
| AR062211A1 (es) | Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas | |
| BR112014011064A2 (pt) | derivados de antibióticos 2-oxo-oxazolidin-3,5-diila | |
| BR112013018732A2 (pt) | novos derivados de amida de aril-benzocicloalquila | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| MX2013007938A (es) | Compuesto biciclico novedoso o sal del mismo. | |
| CO6400145A2 (es) | Derivados de 2-piridin-2-il pirazol-3(2h) -ona, su preparción y su aplicación terapeútica | |
| CO6251285A2 (es) | Derivado de tetrahidroisoquinolina novedoso | |
| CR20160082A (es) | Nuevo derivado de triazina | |
| CO2017003830A2 (es) | Compuestos de piridina | |
| AR081720A1 (es) | Composicion para el control de plagas | |
| CO6481003A2 (es) | Compuesto de benzazepina | |
| AR083861A1 (es) | OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN |